Dr. Dan P. Zandberg
Claim this profileUniversity of Pittsburgh Cancer Institute (UPCI)
Expert in Cancer
Expert in Squamous Cell Carcinoma
18 reported clinical trials
33 drugs studied
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
2Squamous Cell Carcinoma
Global LeaderStage IV
Stage III
PD-L1 positive
Affiliated Hospitals
Clinical Trials Dan P. Zandberg is currently running
Trastuzumab Emtansine
for Salivary Gland Cancer
This phase II trial tests whether ado-trastuzumab emtansine works to shrink tumors in patients with HER2-positive salivary gland cancer that has come back (recurrent), spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Trastuzumab emtansine is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called emtansine. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers emtansine to kill them. Trastuzumab emtansine may work better compared to usual treatment of chemotherapy with docetaxel and trastuzumab in treating patients with salivary gland cancer.
Recruiting1 award Phase 2
Pembrolizumab + Radiation vs Chemotherapy + Radiation
for Head and Neck Cancer
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Recruiting1 award Phase 231 criteria
More about Dan P. Zandberg
Clinical Trial Related1 year of experience running clinical trials · Led 18 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Dan P. Zandberg has experience with
- Cisplatin
- Nivolumab
- Carboplatin
- Pembrolizumab
- Docetaxel
- Intensity-Modulated Radiation Therapy
Breakdown of trials Dan P. Zandberg has run
Cancer
Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Recurrence
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Dan P. Zandberg specialize in?
Dan P. Zandberg focuses on Cancer and Squamous Cell Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Dan P. Zandberg currently recruiting for clinical trials?
Yes, Dan P. Zandberg is currently recruiting for 10 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Dan P. Zandberg has studied deeply?
Yes, Dan P. Zandberg has studied treatments such as Cisplatin, Nivolumab, Carboplatin.
What is the best way to schedule an appointment with Dan P. Zandberg?
Apply for one of the trials that Dan P. Zandberg is conducting.
What is the office address of Dan P. Zandberg?
The office of Dan P. Zandberg is located at: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania 15232 United States. This is the address for their practice at the University of Pittsburgh Cancer Institute (UPCI).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.